Anzeige
Mehr »
Dienstag, 10.02.2026 - Börsentäglich über 12.000 News
Breaking News: Pacifica meldet neue hochgradige Entdeckung und genau deshalb kann der Markt das nicht ignorieren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PM7K | ISIN: US92858K2042 | Ticker-Symbol:
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
VIVOS INC Chart 1 Jahr
5-Tage-Chart
VIVOS INC 5-Tage-Chart

Aktuelle News zur VIVOS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14:36Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel Precision Radionuclide Therapy160Kennewick, WA, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy (PRnT) with its innovative RadioGel technology, today...
► Artikel lesen
03.02.Vivos Inc.: Vivos Inc Updates Human Therapy Progress in India1
28.01.Vivos Inc. Strengthens Patent Protection with New U.S. Patent Issuance and PRECISIONGEL Trademark Approvals1
VIVOS Aktie jetzt für 0€ handeln
22.12.25Vivos Inc.: Vivos Inc Summarizes Progress in its Animal Therapy Division1
22.12.25Vivos Inc.: Vivos Inc Summarzes Preogress in its Animal Therapy Division1
12.11.25VIVOS INC - 10-Q, Quarterly Report-
06.11.25Vivos Inc. Issues Shareholder Update Letter182Kennewick, WA, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) - The Company continues to prioritize securing FDA Investigational Device Exemption (IDE) approval to initiate human clinical...
► Artikel lesen
29.10.25Vivos Inc. Strengthens Strategic Collaboration with Exubrion Therapeutics188Kennewick, WA, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) today announced enhanced cooperation with Exubrion Therapeutics to advance the use of targeted radioactive isotope technology...
► Artikel lesen
27.10.25Vivos Inc. Retains Top FDA Regulatory Expert Dr. John J. Smith, M.D., J.D., to Support IDE Submission for RadioGel1
29.09.25Vivos Inc.: Vivos Inc Board Authorizes Vivos Inc to Establish a Corporate Entity in India2
29.09.25Vivos Inc.: Vivos Inc Board Authorizes Vivios Inc to Establish a Corporate Entity in India141Kennewick, WA, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) The Vivos Board granted authorization to form a wholly owned corporate subsidiary in India. Vivos Inc filed for the name...
► Artikel lesen
18.09.25VIVOS INC - 8-K, Current Report2
08.09.25Vivos Inc. Demonstrates Precision in Precision Radionuclide Therapy131Kennewick, WA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) announced new data demonstrating the exceptional precision of its proprietary Precision Radionuclide Therapy (RadioGel® for...
► Artikel lesen
03.09.25Vivos Inc.: Vivos Inc Files Critical Patent For Hydrogel Electron Beam Sterilization1
14.08.25Vivos Inc.: Investigational Device Exemption (IDE) Application for Human Clinical Trials at Mayo Declined By FDA184Kennewick, WA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) Following the 30-day review period, the FDA declined approval of the Radiogel® IDE submission. We are now focused on addressing...
► Artikel lesen
15.04.25Vivos Inc. Reports Continued Progress in India Human Clinical Trial for RadioGel Precision Radionuclide Therapy336Kennewick, WA, April 15, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to share new developments in its ongoing human clinical trial in India for RadioGel® Precision Radionuclide Therapy...
► Artikel lesen
16 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1